Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TGN-S11 in HPV-associated cancers
NCT05826275Phase 1Completed
- Sponsor
- Toragen, Inc.
- Start
- Jun 2023
- Primary completion
- May 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TGN-S11 in human papillomavirus-associated squamous cell carcinoma (2 arms), sponsored by Toragen, Inc. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Jun 2023; status: completed.
02
Drugs
TGN-S11
03
Conditions
human papillomavirus-associated squamous cell carcinoma
Beyond the preview
Go deeper on NCT05826275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826275.